| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 |
Gland Pharma
Gland Pharma
2,060.70
-41.40
(-1.97%)
Market Cap
33,951.36 Cr
EPS
42.40
PE Ratio
49.64
Dividend Yield
0.86 %
Industry
Healthcare52 Week High
2,220.95
52 Week Low
1,277.80
PB Ratio
3.79
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from12 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,733.80 | #1 4,15,996.70 | 35.83 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 64.93 | |
6,650.00 | 1,76,536.61 | 80.94 | 9,712.00 | 0.89 | 2,191 | 23.05 | 46.65 | |
3,730.60 | 1,26,260.46 | 63.15 | 11,539.40 | 6.99 | 1,911 | 19.91 | 74.11 | |
1,559.40 | 1,25,953.96 | 23.58 | 28,409.50 | 7.12 | 5,291 | 9.88 | 65.36 | |
1,292.10 | 1,07,834.93 | #1 19.10 | 33,741.20 | 16.73 | 5,725 | 1.26 | 55.19 | |
2,575.50 | 1,06,298.29 | 60.68 | 12,744.20 | 19.57 | 2,007 | -10.91 | 55.92 | |
995.15 | 1,00,135.38 | 21.54 | 23,511.00 | 13.82 | 4,615 | -0.19 | 61.25 | |
1,984.60 | 90,635.78 | 27.91 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 58.19 | |
35,195.00 | 74,786.92 | 52.17 | 6,684.70 | 10.80 | 1,414 | 27.83 | 60.78 | |
1,158.00 | 67,256.83 | 19.47 | 31,378.10 | 17.55 | 3,366 | -0.50 | 55.87 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
50.97 %
Net Income Growth
-1.09 %
Cash Flow Change
173.87 %
ROE
-9.79 %
ROCE
-5.23 %
EBITDA Margin (Avg.)
-21.30 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,050 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 | 6,783 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 | 151 |
| Investments | 0 | 0 | 155 | 0 | 0 | 1,685 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 | 0 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 | 1,565 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 | 509 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 |
| Share Capital | 16 | 16 | 16 | 17 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % | 7.39 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % | 32.85 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % | 2.91 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % | 5.02 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Aug 2025 |  Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 2,102.10 |
| 14 Aug 2025 |  Dividend | ₹ 18.00 /share | 14 Aug 2025 | 1,484.15 | 2,102.10 |
| 05 Aug 2025 |  Quarterly Result Announcement | NA | 05 Aug 2025 | 2,000.80 | 2,102.10 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 04 Nov 2024 | Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 30 Aug 2024 | Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 16 Aug 2024 | Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
9 days agoBoard Meeting Intimation for Declaration Of Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 20259 days ago
9 days agoGland Pharma Receives GMP Compliance Certificate From The Danish Medicines Agency For Aseptically Prepared Powder For Injection Infusion And InhalationJul 11, 2025
Jul 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 2025Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Receipt Of EIR From US FDA For Companys JNPC Facility VisakhapatnamJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2025
Jun 09, 2025Update On ANSM Inspection At Cenexis Fontenay Manufacturing FacilityJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
May 27, 2025Grant Of Stock Options (Grant I) Under Gland Pharma Employee Stock Option Scheme 2025 (ESOP 2025 Or Scheme)May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025The 47Th AGM Of The Company Is Scheduled To Be Held On Thursday August 28 2025May 20, 2025
May 20, 2025Board Fixes August 14 2025 As The Record Date For Final DividendMay 20, 2025
May 20, 2025Corporate Action-Board approves DividendMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting - May 20 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
May 20, 2025Intimation Regarding ESOP Compensation Committee MeetingMay 18, 2025
May 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2025
May 06, 2025Board Meeting Intimation for To Approve The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025 And Recommend The Payment Of Final Dividend For FY 2024-25May 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Change In Contact Details Of RTAApr 24, 2025
Apr 24, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 03, 2025
Apr 03, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Mar 31, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2025
Mar 31, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 24, 2025
Mar 24, 2025ESOP Scheme 2025Mar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 11, 2025
Mar 11, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 01, 2025
Mar 01, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 28, 2025
Feb 28, 2025Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of DirectorsFeb 26, 2025
Feb 26, 2025Technical Indicators
RSI(14)
Neutral 76.42
ATR(14)
Volatile 59.84
STOCH(9,6)
Overbought 86.18
STOCH RSI(14)
Neutral 64.75
MACD(12,26)
Bullish 6.98
ADX(14)
Very Strong Trend 52.30
UO(9)
Bearish 56.26
ROC(12)
Uptrend But Slowing Down 13.08
WillR(14)
Overbought -9.68
Mutual Fund Holdings
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth 
Axis ESG Integration Strategy Fund Direct-Growth 
Kotak MNC Fund Direct-Growth 
Mirae Asset Healthcare Fund Direct - Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Aditya Birla Sun Life Equity Hybrid '95 Fund Direct-Growth 
Mahindra Manulife Flexi Cap Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
HDFC MNC Fund Direct - Growth 
Motilal Oswal Nifty Midcap 150 Index Fund Direct - Growth 
Nippon India Nifty Midcap 150 Index Fund Direct - Growth 
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth 
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct - Growth 
SBI Nifty Midcap 150 Index Fund Direct - Growth About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years,
40 days)
Website
Chairperson NameYiu Kwan Stanley Lau
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
